AI assistant
Oric Pharmaceuticals, Inc. — Director's Dealing 2024
Feb 9, 2024
32131_dirs_2024-02-08_f569f5b2-09b2-4afd-8202-4c94f96b5901.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2024-02-06
Reporting Person: Chacko Jacob (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-06 | Common Stock | S | 13958 | $12.1192 | Disposed | 794586 | Direct |
| 2024-02-07 | Common Stock | S | 26042 | $12.2950 | Disposed | 768544 | Direct |
Footnotes
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022.
F2: Represents the weighted average share price of an aggregate total of 13,958 shares sold in the price range of $12.00 to $12.31 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average share price of an aggregate total of 26,042 shares sold in the price range of $12.11 to $12.40 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.